InvestorsHub Logo
Followers 113
Posts 1863
Boards Moderated 0
Alias Born 11/22/2017

Re: Arby2000 post# 583814

Saturday, 04/08/2023 6:26:59 PM

Saturday, April 08, 2023 6:26:59 PM

Post# of 694100
Arby2000

You are right, Matt Williams is a Novocure proponent.
April 2, 2022

Oncologist Dr Matt Williams, who runs the UK’s only clinic to offer Optune – privately – at Charing Cross Hospital in West London, says: ‘We need to be absolutely clear: this treatment works, it’s not a cure, but it makes people live longer. The reason NICE didn’t recommend it is purely an economic decision.’

Each Optune device is, in effect leased from the company, which provides one-on-one support throughout treatment – a package that adds up to a prohibitive £20,000 a month.

‘Drug companies set a price for new treatments, and Novocure has done the same,’ explains Dr Williams.

‘Some of this will be fixed costs, for manufacture and maintenance of the device, and the salary of the support worker. But as with drugs, the company will be looking to make back money they’ve ploughed into research, development and marketing.

‘It’s just too expensive for the NHS, I understand that. But it’s tough, as a clinician, to know there is an effective treatment that I basically can’t tell my patients about because no one can afford it.

‘The company needs to go back to the negotiating table with a lower price. I’m hopeful this will happen.’


https://www.dailymail.co.uk/health/article-10679311/NHS-refuses-fund-mother-twos-brain-tumour-zapper-not-cost-effective.html
I don't think Prof. Susan Short is a huge DCVax-L advocate.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News